is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Detailed information on Vectura Group plc required for business and competitor intelligence needs
A study of the major internal and external factors affecting Vectura Group plc in the form of a SWOT analysis
An in-depth view of the business model of Vectura Group plc including a breakdown and examination of key business segments
Intelligence on Vectura Group plc’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about Vectura Group plc, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Vectura Group (Vectura or 'the group') is engaged in the development of pharmaceutical therapies for the treatment of bronchopulmonary diseases. The group operates in the UK, where it is headquartered in Wiltshire. Vectura employed 216 people as of March 31, 2013. The group recorded revenues of £30.5 million (approximately $48.2 million) during the financial year ended March 2013 (FY2013), a decrease of 7.6% over FY2012. The operating loss of the group was £11.6 million (approximately $18.3 million) in FY2013, as compared to an operating loss of £13.9 million (approximately $22.2 million) in FY2012. The net loss was £5.9 million (approximately $9.3 million) in FY2013, as compared to a net loss of £4.4 million (approximately $7 million) in FY2012.
Reasons to Purchase:
Gain understanding of Vectura Group plc and the factors that influence its strategies
Track strategic initiatives of the company and latest corporate news and actions
Assess Vectura Group plc as a prospective partner, vendor or supplier
Support sales activities by understanding your customers' businesses better
Stay up to date on Vectura Group plc’s business structure, strategy and prospects